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Neocosmospora vasinfecta, a common plant
pathogen in tropical and subtropical areas (1), is
little known as a pathogen in humans. We report
a case of fatal systemic N. vasinfecta infection in
an African patient with leukemia. This is the
third reported case of a human infection with this
organism and the first case in which the infection
was disseminated.
The Case Study
A 38-year-old man was admitted to the
University Hospital of Cologne, Germany, with a
4-week history of fatigue, vertigo, and bone pain.
He had been living in Germany for 15 years and
had returned from a holiday in Nigeria 2 weeks
before admission. Past medical history included
hepatitis C and malaria.
A bone marrow aspirate showed a predomi-
nance of atypical promyelocytes, suggesting
acute nonlymphocytic leukemia FAB M3. The
patient was treated with high-dose all-trans-
retinoic acid for 14 days, followed by a first
induction chemotherapy regimen consisting of
cytarabine, daunorubicine, and thioguanine.
Prophylactic treatment with fluconazole (400 mg/d)
and trimethoprim-sulfamethoxazole (960 mg/d)
was started because severe granulocytopenia,
defined as an absolute neutrophil count below
100/µL of up to 4 weeks’ duration, was anticipated.
Pain projecting to the lateral side of both feet
developed on day 12 of chemotherapy, when the
patient’s absolute neutrophil count had fallen
below 100/µL. His feet were swollen and
hyperthermic. Arthritis and deep vein thrombo-
sis were ruled out. Pain resolved under
symptomatic treatment with acetaminophen. On
day 16 of induction therapy, bone marrow
examination yielded persistence of blast cells.
Therefore, a second induction chemotherapy was
administered, despite ongoing granulocytopenia.
The regimen comprised high-dose cytarabine and
mitoxantrone. On day 16 after the onset of
granulocytopenia, fever developed. Results of a
chest X-ray and a high-resolution computerized
tomography scan were unremarkable. Broad-
spectrum antibiotic treatment was started, but
the fever persisted. Several chest X-rays were
nondiagnostic; however, after 24 days of
granulocytopenia, another computerized tomog-
raphy scan revealed interstitial and patchy lung
infiltrates. Because of persistent fever and newly
developing lung infiltrates under broad-spec-
trum antibiotic therapy, invasive fungal infection
was suspected, and conventional amphotericin B
was administered (1 mg/kg/d). After 1 week of
antifungal therapy, the patient reported bilateral
pleuritic chest pain. Because the patient’s condition
was deteriorating, antifungal therapy was
altered to 2 mg/kg/day liposomal amphotericin B,
but pulmonary infiltrates persisted. Granulocy-
topenia resolved after 34 days, and a bone
marrow aspirate showed complete remission of
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leukemia. On the same day, an abdominal
ultrasound exam revealed hepatosplenomegaly
and hypodensic lesions in the liver, suggesting
possible hepatosplenic involvement of fungal
disease. A lateral purulent ulcerous lesion of the
right foot developed, accompanied by worsening
pain and swelling. Swab cultures revealed a mold
that was not initially identified. Subsequently,
the same mold was isolated from sputum
samples, transtracheal aspirates, a second
biopsy of the foot lesion (Figure 1), and blood
cultures. The patient’s condition deteriorated
rapidly; cholestasis and septic shock developed,
and mechanical ventilation and high doses of
vasopressors were required. Fifteen days after
resolution of neutropenia and while undergoing
antimycotic treatment, the patient died of
multiorgan failure caused by systemic fungal
infection. Consent was not given for autopsy.
Samples were cultivated on Sabouraud agar
at 30°C and 37°C in ambient air. Subcultures
were prepared on malt yeast agar, oatmeal agar,
and potato dextrose agar. The fast-growing,
white-to-pale-buff colonies developed at 26°C and
37°C without special requirements.
The micromorphologic features of the mold,
cultured 3 to 4 days only, resembled a Fusarium
or Acremonium species (Figure 2a). Supported by
subculturing on oatmeal agar with Lupinus sp.,
orange-brown to copper-colored fruiting bodies
developed until day 8 (Figure 2b); after 14 days of
incubation, these bodies were identified as
perithecial ascomata (diameter 200 µm-300 µm).
They contained hyaline cylindrical asci, 9 x 80-
90  µm, with 8 ascospores each (Figure 2c); the
latter were globose to ellipsoidal, pale brown,
rough walled with age, and 8-9 x 10  µm. The
isolate was subsequently identified at the
Centraalbureau voor Schimmelcultures, Baarn,
Netherlands, as a small-spored N. vasinfecta E.F.
Smith var. vasinfecta and was deposited under
the collection number CBS 101957.
Sequence analysis of the internal transcribed
spacer (ITS) region inside the nuclear rDNA was
performed. DNA was extracted by sonication in
CTAB buffer (cetyl trimethyl ammonium bro-
mide) (2) and amplified with the primer pair
ITS5/ITS4. The polymerase chain reaction
Figure 2. A) Neocosmospora vasinfecta after 4 days’
subculture on Sabouraud agar (lactophenol cotton blue
stain, x400). B) N. vasinfecta perithecial ascomata after 4
weeks on oatmeal agar with lupine stem (x160). C) Asci
with ascospores of N. vasinfecta (x400).
Figure 1. Biopsy of foot lesion: area of extended dermal
necrosis with inflammatory infiltration. In the center,
PAS-(periodic acid-Schiff stain)positive septate hy-
phae branching at an acute angle (x400).
A
B
C151 Vol. 7, No. 1, January–February 2001 Emerging Infectious Diseases
Dispatches
product was purified from agarose gel by using
the Gel Extraction Kit (Qiagen GmbH, Hilden,
Germany) and directly sequenced with the primers
ITS2, ITS3, ITS4, and ITS5 (3). DNA sequencing
was performed by the dideoxynucleotide termi-
nation method, using the dye deoxy terminator
chemistry and the ABI 377 automated sequencer
(PE Applied Biosystems, Foster City, CA). The
results were compared with the published ITS
sequence, GenBank accession no. L36627.
When we compared our results to the
published 544-bp ITS sequence, we found
differences in three positions: T to C exchange at
nucleotide position 72, C to T exchange at
position 102, and an insertion of a seventh
C between positions 381 and 388.
The MICs of amphotericin B and 5-
flucytosine were determined by the ATB Fungus
kit (Biomérieux SA, Marcy l’Étoile, France).
Susceptibility testing to fluconazole, itraconazole,
terbinafine, and voriconazole (Pfizer Inc., New
York, NY) was performed by using a casitone-
based microdilution system (4). The MIC for
itraconazole was simultaneously determined
according to the National Committee for Clinical
Laboratory Standards (NCCLS) M27-A protocol
(5). The inoculum had a final amount of 1x104
conidia per microliter. Incubation time at 35°C
was 44 hours for amphotericin B and 5-flucytosine
and 30 hours for the other antifungals.
MICs were as follows: amphotericin B > 8 µg/
mL-1, 5-flucytosine >128 µg/mL-1, fluconazole
>128 µg/mL-1, itraconazole >2 µg/mL-1 versus >8
µg/mL-1 (according to NCCLS), voriconazole 1 µg/
mL-1 , and terbinafine 0.125 µg/mL-1.
Conclusions
In the early days of incubation, the
micromorphologic features of N. vasinfecta
isolates may be misleading, suggesting Fusarium
or Acremonium species (1), which could lead to an
inadequate therapeutic regimen because of the
different amphotericin B susceptibility of these
genera. While high-dose amphotericin B intrave-
nously is the first-line therapy in systemic
fusarioses, polyene antimycotics are probably
not  beneficial against infections caused by
N. vasinfecta, as demonstrated in our patient and
in a recently reported immunocompetent patient
with posttraumatic N. vasinfecta infection (6).
Our patient died of disseminated infection by
N. vasinfecta despite high-dose antimycotic
therapy with amphotericin B and remission of
the underlying hematologic malignancy. The in
vitro susceptibility test results confirmed the
resistance of the isolate against amphotericin B
and fluconazole and nearly all of the few other
antifungal agents available for systemic therapy.
Not enough data on terbinafine are available to
allow valid interpretation. In comparison to the
MICs of voriconazole against other filamentous
fungi such as Aspergillus fumigatus (7), the
susceptibility for voriconazole in our isolate
might not have been sufficient for adequate
antifungal treatment.
Neither the mechanism of infection nor the
incubation period could be determined. Our
patient did not remember any injury, so infection
most likely occurred through minimal trauma.
Although he might have been infected during his
recent stay in Nigeria, infection might have
occurred in Africa considerably longer ago: The
latency period for N. vasinfecta can be several
years between infection and the symptomatic
stage (8). The infection might never have been
detected had the patient remained immunocom-
petent. Once the infection became systemic, it
was likely incurable.
The two previously reported patients (6,8,9),
both from Senegal, had been cured by a radical
surgical intervention that prevented dissemina-
tion of disease, limiting it to the lower
extremities. Because of the poor susceptibility of
the fungus, complete surgical excision prompted
by early diagnosis is the only means to influence
the clinical outcome. Currently, no medical
treatment option exists for a patient with
systemic disease caused by N. vasinfecta.
Imported mycoses should be taken into
consideration in patients who have traveled or
lived abroad, especially former residents of
tropical and subtropical countries, even years
after their stay abroad. Recent epidemiologic
data on plants suggest that persons working in
cotton production might also be at risk (10).
This is the first case of disseminated
N. vasinfecta infection. Physicians may consider
this infection as a new differential diagnosis of
purulent subcutaneous leg lesions in the severely
immunocompromised host.
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